帕比司他联合卡非佐米治疗复发或复发难治多发性骨髓瘤的I/II期研究:第二剂量扩展队列最终分析
该I/II期单臂多中心研究采用标准3+3剂量递增扩展队列设计,评估帕比司他联合卡非佐米治疗复发或复发难治多发性骨髓瘤。扩展队列可评估患者总缓解率为84.4%,中位无进展生存期10.3个月,中位总生存期44.6个月。常见不良事件包括血小板减少、恶心、疲乏、腹泻和呕吐。
要点
- 帕比司他联合卡非佐米在复发或复发难治多发性骨髓瘤中总缓解率达84.4%。
- 中位无进展生存期10.3个月,中位总生存期44.6个月。
- 常见不良事件为血小板减少、恶心、疲乏、腹泻和呕吐。
核心结论
- 帕比司他联合卡非佐米是复发或复发难治多发性骨髓瘤的有效免激素方案。
研究设计与样本
- I/II期单臂多中心标准3+3剂量递增扩展队列研究(NCT01496118)。
- DL6组33例接受帕比司他20 mg联合卡非佐米20/56 mg/m2,另3例接受帕比司他30 mg联合卡非佐米20/56 mg/m2。
- 扩展队列可评估患者32例,中位年龄63岁,42.4%为高危,中位既往治疗2线。
主要发现
- 扩展队列可评估患者总缓解率84.4%,临床获益率90.6%。
- 中位随访26.1个月,中位无进展生存期10.3个月(95%CI 6.1-13.9)。
- 中位至进展时间11.7个月(95%CI 5.6-14.5),中位总生存期44.6个月(95%CI 20.8-N/A)。
- 常见不良事件包括血小板减少78.8%、恶心63.6%、疲乏63.6%、腹泻51.5%、呕吐51.5%。
- 7例患者发生严重治疗相关不良事件,1例治疗相关死亡。
关键数值与推荐
- 扩展队列可评估患者总缓解率84.4%,临床获益率90.6%。
- 中位无进展生存期10.3个月(95%CI 6.1-13.9),中位总生存期44.6个月(95%CI 20.8-N/A)。
- 常见不良事件:血小板减少78.8%、恶心63.6%、疲乏63.6%、腹泻51.5%、呕吐51.5%。
临床怎么用
- 对于复发或复发难治多发性骨髓瘤,可考虑帕比司他联合卡非佐米作为免激素治疗选择。
- 治疗期间需监测血小板减少、恶心、疲乏、腹泻和呕吐等不良事件。
局限性
- 本研究为单臂研究,未设对照组。
- 样本量较小,扩展队列可评估患者仅32例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The maximum tolerated dose of the panobinostat and carfilzomib combination in patients with relapsed/refractory multiple myeloma (RRMM) was not reached in our previous dose-escalation study. We report additional dose levels in the phase I/II, single-arm, multicenter, standard 3 + 3 dose-escalation expansion-cohort study (NCT01496118). Patients with RRMM were treated with panobinostat 30 mg, carfilzomib 20/56 mg/m2 (N = 3), or panobinostat 20 mg, carfilzomib 20/56 mg/m2 (N = 33). Treatment cycles lasted 28 days; panobinostat: days 1, 3, 5, 15, 17, 19; carfilzomib: days 1, 2, 8, 9, 15, 16. For dose level 6 (DL 6), median age was 63 years (range, 49-91 years), 60.6% were male, 42.4% were high risk. Patients received a median of two prior therapies (range 1-7); proteasome inhibitors (PI; 100%), immunomodulatory imide drugs (IMiD; 78.8%), and stem cell transplant (36.4%); 48.5%, 51.1%, and 24.2% were refractory to prior PI or prior IMiD treatment or both, respectively. Patients completed a median of seven (range 1-40) treatment cycles. Overall response rate (primary endpoint) of evaluable patients in the expansion cohort (N = 32): 84.4%; clinical benefit rate: 90.6%. With a median follow-up of 26.1 months (range, 0-72.5 months), median (95% CI) progression-free survival, time-to-progression and overall survival of patients was 10.3 (6.1, 13.9), 11.7 (5.6, 14.5), and 44.6 (20.8, N/A) months, respectively. Common adverse events (AEs) included thrombocytopenia (78.8%), nausea (63.6%), fatigue (63.6%), diarrhea (51.5%), and vomiting (51.5%). Seven patients had serious treatment-related AEs. There was one treatment-related death. In conclusion, panobinostat plus carfilzomib is an effective steroid-sparing regimen for RRMM.
引用
- Berdeja JG, Gregory TK, Faber EA, et al. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. Am J Hematol. 2021. PMID: 33421178. doi:10.1002/ajh.26088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。